{"nctId":"NCT00529451","briefTitle":"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","startDateStruct":{"date":"2007-09"},"conditions":["Hypertension"],"count":1613,"armGroups":[{"label":"Aliskiren 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren"]},{"label":"Aliskiren 150 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren"]},{"label":"Aliskiren 75 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren"]},{"label":"Ramipril 5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ramipril"]}],"interventions":[{"name":"Aliskiren","otherNames":[]},{"name":"Ramipril","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have msDBP ≥ 90 mmHg and \\< 110 mmHg at the visit immediately prior to Visit 3\n* Patients must have msDBP \\>OR= 95 mmHg and \\< 110 mmHg at Visit 3\n* Patients must have an absolute difference of \\< or =10 mmHg in their mean sitting diastolic blood pressure (msDBP) from Visit 2 to Visit 3\n\nExclusion Criteria:\n\n* Severe hypertension (grade 3 WHO classification; msDBP \\>or= 110 mmHg and/or msSBP \\>or = 180 mmHg).\n* History or evidence of a secondary form of hypertension.\n* History of transient ischemic cerebral attack within 12 months of visit 1.\n* Current angina pectoris requiring pharmacological therapy (other than those patients on a stable dose of oral or topical nitrates)\n* Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) \\> 8% at Visit 1.\n* Known or suspected contraindications to the study medications, including history of allergy to ramipril or other ACE Inhibitors.\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint","description":"To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.39","spread":"0.66"},{"groupId":"OG001","value":"-12.16","spread":"0.67"},{"groupId":"OG002","value":"-12.24","spread":"0.66"},{"groupId":"OG003","value":"-11.46","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.63","spread":"0.44"},{"groupId":"OG001","value":"-10.04","spread":"0.44"},{"groupId":"OG002","value":"-10.66","spread":"0.44"},{"groupId":"OG003","value":"-9.19","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of < 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg","description":"To evaluate the percentage of patients controlled to a target blood pressure of \\< 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.29","spread":null},{"groupId":"OG001","value":"48.11","spread":null},{"groupId":"OG002","value":"45.68","spread":null},{"groupId":"OG003","value":"43.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP < 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP","description":"To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP \\< 90 mmHg or ≥ 10mmHg decrease from baseline in msDBP.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.89","spread":null},{"groupId":"OG001","value":"59.75","spread":null},{"groupId":"OG002","value":"59.57","spread":null},{"groupId":"OG003","value":"53.87","spread":null}]}]}]},{"type":"PRIMARY","title":"Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)","description":"To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.63","spread":"0.44"},{"groupId":"OG001","value":"-9.19","spread":"0.44"}]}]}]},{"type":"PRIMARY","title":"Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)","description":"To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.04","spread":"0.44"},{"groupId":"OG001","value":"-9.19","spread":"0.44"}]}]}]},{"type":"PRIMARY","title":"Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)","description":"To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.66","spread":"0.44"},{"groupId":"OG001","value":"-9.19","spread":"0.44"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":331},"commonTop":["Cough"]}}}